Biotechnology Viral Vector Vaccine Law In Russia.

1. Introduction

Viral vector vaccine law in Russia is a branch of pharmaceutical, biotechnology, public health, medical-product regulation, intellectual property and administrative law. It governs the research, development, clinical testing, registration, manufacture, distribution, administration and post-marketing monitoring of vaccines that use genetically modified viral vectors to stimulate an immune response.

A viral vector vaccine uses a modified virus as a delivery vehicle to introduce genetic instructions into human cells. The vector is designed to deliver an antigen-related genetic sequence and stimulate the immune system. Depending on the technology, the vector may be replication-deficient or replication-competent.

Russia is particularly significant in this field because of the development of Sputnik V (Gam-COVID-Vac), a COVID-19 vaccine using two different adenovirus vectors:

First component: recombinant human adenovirus type 26 (rAd26).

Second component: recombinant human adenovirus type 5 (rAd5).

The Russian legal framework does not generally create an entirely separate statutory category for viral vector vaccines. Instead, these products are principally regulated as immunobiological medicinal products under pharmaceutical and public-health legislation.

The principal legal concerns include:

Vaccine safety and efficacy.

Genetic engineering and biological containment.

Clinical trial authorization and informed consent.

State registration and emergency authorization.

Manufacturing quality and pharmaceutical inspections.

Vaccine injury compensation.

Intellectual property and technology transfer.

Government accountability and judicial review.

International and Eurasian Economic Union regulatory compliance.

2. Principal Legislative Framework

A. Federal Law No. 61-FZ of 12 April 2010 – On Circulation of Medicines

This is the central legislation governing viral vector vaccines in Russia.

It regulates:

Development of medicinal products.

Preclinical research.

Clinical trials.

Pharmaceutical examination.

State registration.

Manufacturing and quality control.

Storage and transportation.

Import and export.

Distribution and medical use.

Pharmacovigilance and safety monitoring.

Under Article 4, vaccines fall within the framework of immunobiological medicinal products.

Article 13 establishes the general requirement for state registration before medicinal products can be placed into ordinary civil circulation, subject to applicable statutory exceptions and special procedures.

Articles 11 and 12 address preclinical testing, while Articles 38–43 establish important requirements for clinical trials and patient protection.

For viral vector vaccines, these provisions are important because regulators must evaluate the vector's biological characteristics, genetic stability, immunogenicity, safety and potential adverse effects.

WIPO+2

B. Federal Law No. 323-FZ of 21 November 2011 – Fundamentals of Public Health Protection

This law establishes the general legal framework for medical treatment, patient rights and healthcare accountability.

Its relevance includes:

Informed consent before medical intervention.

Medical confidentiality.

Patient rights.

Medical organization responsibilities.

Quality and safety of healthcare.

Government supervision of medical activities.

A vaccine's registration does not eliminate the duty of medical professionals to provide appropriate information and comply with medical standards.

cis-legislation.com+1

C. Federal Law No. 157-FZ of 17 September 1998 – Immunoprophylaxis of Infectious Diseases

This legislation provides the specific public-health framework for preventive vaccination.

It addresses:

State immunization policy.

Preventive vaccinations.

National vaccination schedules.

Voluntary vaccination.

Medical contraindications.

Vaccine-related complications.

Social protection and compensation.

The law is especially important where viral vector vaccines are included in national immunization programmes.

cis-legislation.com+1

D. Federal Law No. 180-FZ of 23 June 2016 – Biomedical Cellular Products

This legislation regulates biomedical cellular products, including their development, research, registration and use.

However, ordinary medicinal vaccines are generally governed by Federal Law No. 61-FZ. The 180-FZ framework should not automatically be applied to viral vector vaccines merely because they involve genetic engineering or biological materials.

cis-legislation.com+1

3. Regulatory Authorities Responsible for Viral Vector Vaccines

Several government institutions have important regulatory responsibilities.

Regulatory authorityPrincipal responsibility
Ministry of Health of RussiaPharmaceutical policy, vaccine registration and clinical-trial authorization
RoszdravnadzorPharmaceutical quality, safety monitoring and batch-release supervision
RospotrebnadzorSanitary and epidemiological supervision
Ministry of Industry and TradeIndustrial and pharmaceutical manufacturing policy
Federal Antimonopoly ServiceCompetition and pharmaceutical-market regulation
Russian courtsJudicial review, compensation and enforcement of legal rights

The Ministry of Health is particularly important for registration, while Roszdravnadzor supervises the quality and safety of medicinal products.

4. Legal Regulation of Viral Vector Vaccine Development

A. Preclinical Research

Before a viral vector vaccine can enter human clinical trials, its developer must establish an adequate scientific and safety basis.

Preclinical investigations generally examine:

Biological characteristics of the viral vector.

Genetic stability.

Antigen expression.

Immunogenicity.

Toxicity and potential adverse reactions.

Biodistribution and persistence.

Potential unintended biological effects.

Reproductive and developmental safety where relevant.

For adenovirus-based vaccines, developers must also investigate whether the vector retains unintended replication capacity and whether pre-existing immunity against the vector could affect vaccine performance.

Under Federal Law No. 61-FZ, preclinical research must comply with applicable good laboratory practice requirements.

Legal significance: A manufacturer cannot rely exclusively on the general safety history of adenovirus technology. The particular vector, genetic construct, manufacturing process and final vaccine formulation must be adequately evaluated.

B. Genetic Engineering and Biological Safety

Viral vector vaccines involve genetic engineering, making biological safety an important regulatory consideration.

Russia's Federal Law No. 86-FZ of 5 July 1996, concerning state regulation in the field of genetic engineering activities, is relevant to certain genetic engineering activities.

The applicable requirements depend on the nature of the organism, the research activity, the facility and the intended use.

Important regulatory concerns include:

Safe handling of genetically modified organisms.

Prevention of accidental biological release.

Laboratory containment.

Occupational safety.

Environmental protection.

Transport of biological materials.

Appropriate waste disposal.

A distinction must be maintained between the regulation of genetically modified organisms and the regulation of medicinal products. A vaccine's pharmaceutical registration does not automatically resolve every separate biosafety obligation.

C. Clinical Trial Authorization

Clinical trials are governed primarily by Articles 38–43 of Federal Law No. 61-FZ.

A developer must comply with the relevant authorization, ethical review and clinical-trial requirements.

Clinical investigations generally involve:

Phase I: Initial human safety and tolerability assessment.

Phase II: Evaluation of immunogenicity, dosage and safety in a larger population.

Phase III: Assessment of protective efficacy and safety in a substantially larger population.

Phase IV: Post-registration monitoring and further investigation of safety and effectiveness.

The legal requirements include:

Approval of the clinical-trial protocol.

Appropriate medical institution accreditation.

Qualified investigators.

Ethical examination.

Informed consent.

Medical supervision.

Documentation of adverse events.

Protection of confidential patient information.

Article 43 is particularly significant because participation must be voluntary. Patients must receive written information about the medicine, anticipated benefits, potential risks, trial duration and insurance arrangements.

Patients may withdraw from clinical trials at any stage.

WIPO+2

5. Sputnik V and the Legal Importance of Viral Vector Vaccines

Russlands Impfdiplomatie - Sputnik V für die Welt

 

 

Photo | Official website vaccine against COVID-19 Sputnik V.

 

 

Центр Гамалеи изучает вариант создания вакцины от COVID на основе нескольких штаммов - 16.01.2022, Sputnik Абхазия

 

7

 

The most prominent Russian example is Sputnik V (Gam-COVID-Vac).

It was developed by the Gamaleya National Research Centre.

Its two-component design uses recombinant adenovirus vectors Ad26 and Ad5.

Legal issues arising from Sputnik V

1. Conditional registration

The vaccine was registered in Russia in August 2020 under a special pandemic-era regulatory framework.

This raised questions about the relationship between rapid registration, incomplete clinical development and the protection of public health.

Conditional registration does not mean that all ordinary pharmaceutical quality and safety obligations disappear.

2. Post-registration clinical monitoring

Post-registration studies were important for obtaining further evidence about vaccine safety and effectiveness.

3. Batch quality control

Russian authorities established a system under which immunobiological medicinal products, including vaccines, require quality assessment of individual batches before release into civil circulation.

4. Public accountability

The registration and administration of Sputnik V raised important questions about regulatory transparency, scientific evidence, patient consent and government responsibility.

Roszdravnadzor publicly described the registration and post-registration monitoring arrangements, including the planned clinical investigation involving approximately 2,000 participants and batch-level quality controls.

09reg.roszdravnadzor.ru+1

 

6. State Registration and Emergency Authorization

State registration is a central legal requirement under Article 13 of Federal Law No. 61-FZ.

The registration assessment concerns:

Pharmaceutical quality.

Safety.

Efficacy.

Manufacturing consistency.

Clinical evidence.

Risk-benefit balance.

Product information and instructions.

Article 27 provides for decisions on registration or refusal following expert assessment.

Article 36 provides for the possibility of appealing certain decisions refusing clinical-trial authorization or state registration.

Special pandemic registration

During the COVID-19 pandemic, Russia introduced special and simplified procedures under Government Resolution No. 441 of 3 April 2020, as subsequently amended.

These procedures permitted conditional registration subject to specified obligations.

However, emergency or conditional registration should not be confused with unrestricted permission to manufacture and distribute any viral vector vaccine.

The developer remains responsible for complying with applicable registration conditions, safety requirements and post-registration obligations.

WIPO+2

7. Manufacturing, GMP and Batch Release

Manufacturing is another major area of viral vector vaccine law.

Viral vector vaccine manufacturers must maintain control over:

Cell substrates and production systems.

Viral seed stocks.

Genetic identity and stability.

Purity and potency.

Residual host-cell DNA and proteins.

Adventitious agents.

Sterility and contamination.

Batch consistency.

Storage and transportation conditions.

Good Manufacturing Practice (GMP) requirements are important throughout the production process.

The Eurasian Economic Union pharmaceutical regulatory framework is also relevant. Its common rules include requirements concerning medicinal-product registration, GMP and pharmaceutical quality.

Batch-release requirement

Article 52.1 of Federal Law No. 61-FZ is particularly important for immunobiological medicinal products.

The framework requires the relevant quality assessment and authorization for individual batches before their release into civil circulation.

This is especially important for viral vector vaccines because a manufacturing deviation may affect the biological properties, purity or potency of the finished product.

The Russian regulatory system therefore treats vaccine quality control as a continuing obligation rather than a one-time registration exercise.

ICLRC+1

 

8. Vaccine Injury Compensation and Manufacturer Liability

Vaccine injury is one of the most significant legal issues.

Russian law distinguishes between:

Compensation under the statutory social-support scheme.

Civil liability arising from defective products.

Liability for medical negligence.

Liability for violations of clinical-trial obligations.

A. Federal Law No. 157-FZ

Articles 19–21 establish social-support mechanisms for qualifying post-vaccination complications.

According to the statutory framework described by the University of Oxford's vaccine-compensation research:

CircumstanceStatutory compensation
Qualifying post-vaccination complicationRUB 10,000 lump sum
Death resulting from a post-vaccination complicationRUB 30,000 to eligible family members
Disability caused by a qualifying complicationRUB 1,000 monthly
Temporary disability associated with a post-vaccination complicationTemporary disability benefit calculated at 100% of average earnings

Eligibility depends on the applicable statutory requirements and medical evidence.

The compensation system is particularly relevant to COVID-19 vaccination because COVID-19 vaccination was included in the national vaccination framework for epidemic indications in December 2020.

Faculty of Law+1

B. Manufacturer's Civil Liability

A manufacturer may face liability where a vaccine is defective, improperly manufactured, inadequately labelled or otherwise unlawfully supplied.

Relevant legal sources include:

Civil Code of the Russian Federation.

Consumer Protection Law No. 2300-1 of 7 February 1992.

Federal Law No. 61-FZ.

Applicable medical and pharmaceutical regulations.

Potential claims may involve:

Defective manufacturing.

Contamination.

Incorrect dosage.

Inadequate safety information.

Failure to report serious adverse events.

Breach of contractual obligations.

Negligent handling or administration.

An important distinction is that a vaccine injury does not automatically establish manufacturer negligence. Causation, product defect and the applicable legal basis of liability must be examined separately.

9. Important Russian Judicial Decisions and Case Laws

There is an important limitation in Russian viral-vector vaccine jurisprudence: publicly identifiable reported judgments directly deciding the legality of Sputnik V's adenovirus-vector technology or its original registration are limited. Nevertheless, Russian courts have decided vaccine-related disputes that establish useful principles for viral vector vaccine litigation.

The following decisions are particularly relevant.

Case 1: Andreeva v. Central District Hospital of Salsk District

Relevant vaccine-administration precedent

Court: Fourth Cassation Court of General Jurisdiction.

Date: 6 October 2022.

Case No.: 8Г-25733/2022 (88-30744/2022).

Facts:

The claimant received the first component of the CoviVac vaccine on 19 August 2021.

On 2 September 2021, she returned to receive the second component of CoviVac. However, medical personnel mistakenly administered the second component of Gam-COVID-Vac (Sputnik V).

The two vaccines had different technologies and manufacturers.

The claimant alleged that the error caused psychological distress and uncertainty about the consequences of receiving components from two different vaccines.

Legal issues:

Whether the hospital provided an inadequate medical service.

Whether administering an incompatible or unstudied vaccine combination constituted medical negligence.

Whether the patient was entitled to compensation for non-pecuniary harm.

Judicial significance:

The lower court found that the vaccination service had been provided inadequately and awarded RUB 20,000 in moral damages.

The cassation proceedings examined the claimant's challenge to the handling and assessment of her claims.

Principle:

Medical personnel must administer the vaccine prescribed for the patient and maintain accurate vaccination records. An error in vaccine administration may create liability even without proof of a conventional manufacturing defect.

Relevance to viral vector vaccine law:

This decision is especially relevant to Sputnik V because it concerns the administration of Gam-COVID-Vac and the legal risks associated with mixing different vaccine products.

ГАРАНТ

Case 2: Krasnogorsk City Court – Post-Vaccination Paralytic Poliomyelitis Litigation

Court: Krasnogorsk City Court, Moscow Region.

Decision date: 22 April 2024.

Subsequent proceedings: Moscow Regional Court.

Subject: Vaccine-associated paralytic poliomyelitis and medical negligence.

Facts:

The claimant became disabled following a childhood polio vaccination.

The claim alleged that vaccination had been administered while the child was suffering from an acute respiratory viral infection.

A medical expert commission concluded that vaccine-associated paralytic poliomyelitis had developed following the second polio vaccination.

The experts also distinguished between complications arising despite proper vaccination and complications potentially associated with medical errors, including failure to observe contraindications.

They identified deficiencies in the informed-consent documentation, including inadequate information about potential risks and alternative medical interventions.

Legal significance:

The proceedings illustrate three important legal principles:

A vaccine complication may occur even when medical personnel follow proper procedures.

Vaccination in the presence of contraindications may create medical negligence liability.

Informed consent must contain meaningful information about material risks and possible consequences.

Relevance to viral vector vaccines:

The case concerned polio vaccination, not an adenovirus-based vaccine. Nevertheless, its reasoning is relevant to claims involving viral vector vaccines, particularly where a patient alleges inadequate screening, deficient risk disclosure or improper administration.

oblsud--mo.sudrf.ru

Case 3: Russian Vaccine Compensation Framework – Federal Law No. 157-FZ and Government Resolution No. 1013

This is a statutory compensation framework rather than a single judicial judgment.

Government Resolution No. 1013 of 27 December 2000 establishes the procedure for paying state lump-sum benefits and monthly monetary compensation for qualifying post-vaccination complications.

Legal significance:

It provides an administrative route for eligible injured vaccine recipients and family members of deceased recipients.

Disputes concerning compensation payments may be resolved through the procedures established by Russian law, including judicial proceedings.

This framework is relevant to qualifying viral vector vaccine injuries where the relevant vaccine and complication fall within the statutory coverage.

Faculty of Law

Comparative analysis of the cases

Legal issueCase or frameworkPrinciple
Wrong vaccine administrationAndreeva, 2022Medical-service liability
Vaccine-associated injuryKrasnogorsk, 2024Causation and expert evidence
Informed consentKrasnogorsk, 2024Disclosure of material risks
Statutory compensationLaw No. 157-FZSocial support for qualifying injuries
Manufacturer liabilityCivil and pharmaceutical lawProduct defect and causation

These decisions should not be cited as judgments establishing the scientific or regulatory validity of Sputnik V. Their relevance lies in the broader principles governing vaccination, patient rights and compensation.

10. Pharmacovigilance and Post-Marketing Surveillance

Pharmacovigilance is essential because some adverse effects may only become apparent after a vaccine has been administered to a large population.

Under the pharmaceutical regulatory framework, the developer and other responsible participants must comply with applicable adverse-event reporting and safety-monitoring obligations.

Important issues include:

Detection of unexpected adverse reactions.

Reporting of serious adverse events.

Investigation of suspected vaccine-related injuries.

Periodic safety assessments.

Evaluation of changes in the benefit-risk balance.

Regulatory corrective action.

Possible suspension or withdrawal of authorization.

For viral vector vaccines, monitoring should also consider vector-specific concerns, including immune responses against the vector and the possibility of rare biological complications.

A manufacturer cannot avoid responsibility merely because an adverse reaction was identified after registration.

11. Intellectual Property and Patent Protection

Viral vector vaccines involve substantial intellectual property interests.

Russian intellectual property law, particularly Part IV of the Civil Code, protects eligible biotechnology inventions.

Potentially protectable subject matter includes:

Novel viral vector constructs.

Genetic sequences and modifications meeting patentability requirements.

Vaccine formulations.

Manufacturing methods.

Stabilization techniques.

Delivery systems.

Novel production technologies.

However, patentability is not automatic.

A patent application must satisfy the applicable requirements of novelty, inventive step and industrial applicability. The exclusion relating to inventions contrary to public interest, humanitarian principles or morality may also be relevant.

Patent disputes

Potential litigation may involve:

Unauthorized use of patented vector technology.

Patent ownership disputes between research institutions and developers.

Employee inventions.

University research commercialization.

Licensing and royalty arrangements.

Technology-transfer agreements.

Compulsory licensing under applicable Russian law.

Legal example: If a biotechnology company uses a patented adenovirus-vector manufacturing process without authorization, the patent holder may seek remedies under the Russian Civil Code.

The public-health importance of a vaccine does not automatically eliminate patent rights, although applicable statutory exceptions and compulsory-licensing provisions may affect enforcement.

12. International and Eurasian Economic Union Regulation

Russia's viral vector vaccine industry is also affected by international regulatory obligations.

A. Eurasian Economic Union

The Eurasian Economic Union (EAEU) pharmaceutical framework is relevant to the registration and circulation of medicinal products.

The EAEU common-market rules include:

Common pharmaceutical registration requirements.

Quality standards.

GMP requirements.

Pharmacovigilance.

Regulatory recognition procedures.

The transition to the EAEU common pharmaceutical market is particularly important for companies seeking to distribute viral vector vaccines across member states.

ICLRC+1

B. Biological Safety and International Cooperation

International cooperation may involve:

Sharing vaccine research.

Transfer of biological materials.

Clinical-trial collaboration.

Technology licensing.

Manufacturing partnerships.

Cross-border distribution.

The Cartagena Protocol on Biosafety may become relevant where the activity falls within its scope concerning living modified organisms and transboundary movements.

However, it should not be assumed that every finished viral vector vaccine automatically falls within the Protocol's scope. The legal classification of the particular biological material and activity is essential.

C. International Clinical Trials

Russian law permits international multicentre clinical trials subject to the applicable domestic authorization and regulatory requirements.

Article 39 of Federal Law No. 61-FZ addresses international multicentre and post-registration clinical trials.

This is relevant when Russian biotechnology developers collaborate with foreign research institutions or conduct multinational vaccine studies.

13. Constitutional and Human Rights Issues

Viral vector vaccine regulation also raises constitutional questions.

A. Right to Health

Article 41 of the Russian Constitution recognizes the right to health protection and medical assistance.

The government must maintain a legal framework for vaccine safety, access to medical treatment and public-health protection.

B. Personal Autonomy

Article 21 protects human dignity, while Article 22 protects personal liberty and inviolability.

These constitutional guarantees are relevant to questions of medical intervention, consent and bodily autonomy.

C. Privacy and Genetic Information

Viral vector vaccine research may involve the collection of biological samples and genetic or other sensitive medical information.

The relevant legal framework includes:

Federal Law No. 152-FZ of 27 July 2006 on Personal Data.

Federal Law No. 323-FZ on Public Health Protection.

Applicable clinical-trial confidentiality requirements.

Researchers and medical institutions must comply with applicable rules governing the processing, storage and disclosure of patient information.

D. Mandatory Vaccination and Employment

Federal Law No. 157-FZ permits certain preventive vaccination requirements for specified occupational groups and circumstances.

However, the legal consequences of refusing vaccination must be assessed under the applicable legislation, including employment law, public-health rules and constitutional protections.

A distinction must be maintained between mandatory vaccination requirements for particular activities and an unrestricted power to compel every person to undergo vaccination.

14. Administrative and Regulatory Enforcement

Russian authorities can take regulatory action when a viral vector vaccine violates pharmaceutical or public-health requirements.

Possible enforcement measures include:

Regulatory violationPossible legal consequence
Unauthorized clinical trialRegulatory enforcement
Falsification of trial dataAdministrative or criminal liability, depending on the conduct
Manufacturing without required authorizationSuspension or other statutory sanctions
GMP violationsCorrective measures and manufacturing restrictions
Contaminated vaccine batchesBatch rejection or recall
Failure to report adverse eventsRegulatory liability
Unlawful advertisingAdvertising-law enforcement
Unauthorized patent exploitationCivil intellectual-property remedies

The exact penalty depends on the applicable statutory provision, the seriousness of the violation and the responsible party's conduct.

15. Major Legal Challenges in Russia

Several continuing legal challenges deserve attention.

1. Rapid vaccine development versus scientific evidence

Emergency registration creates a difficult balance between urgent public-health needs and the requirement for reliable clinical evidence.

2. Viral vector safety

Regulators must distinguish between the risks associated with the viral vector itself and those associated with the antigen, formulation and manufacturing process.

3. Long-term safety monitoring

Long-term monitoring is necessary to identify uncommon or delayed adverse effects.

4. Manufacturing consistency

A vaccine's safety and efficacy depend on maintaining consistent biological and pharmaceutical characteristics between production batches.

5. Patient compensation

The statutory compensation scheme does not necessarily resolve every claim involving severe injury, medical negligence or defective manufacturing.

6. International regulatory recognition

Registration in Russia does not automatically establish approval in another jurisdiction.

7. Patent ownership and technology transfer

International sanctions, licensing restrictions and cross-border research partnerships may complicate the commercialization of Russian biotechnology inventions.

8. Regulatory transparency

Access to clinical-trial information, manufacturing records and safety assessments is important for public confidence and meaningful regulatory accountability.

16. Recommendations for Reform

The following measures could strengthen the Russian legal framework:

Introduce more detailed statutory guidance specifically addressing viral vector vaccine development.

Improve public access to clinical-trial results and safety reports.

Strengthen independent scientific review of conditional vaccine registrations.

Improve transparency in the investigation of serious adverse events.

Establish clearer standards for genetic stability and vector-specific biological risks.

Strengthen compensation procedures for qualifying vaccine injuries.

Improve judicial access to independent medical and scientific expertise.

Establish clearer legal rules for international technology transfer.

Strengthen GMP inspections and batch-release transparency.

Improve protection of patient genetic and biological information.

17. Conclusion

Biotechnology Viral Vector Vaccine Law in Russia is principally governed by Federal Law No. 61-FZ, Federal Law No. 157-FZ and Federal Law No. 323-FZ, supplemented by genetic-engineering legislation, pharmaceutical regulations and EAEU requirements.

Sputnik V demonstrates the importance of this framework. Its development and registration raised significant questions about conditional authorization, clinical evidence, manufacturing quality, pharmacovigilance, patient consent and international recognition.

Russian judicial decisions, including Andreeva v. Central District Hospital of Salsk District (2022) and the Krasnogorsk post-vaccination paralytic poliomyelitis litigation (2024), provide relevant principles concerning medical negligence, vaccine administration, informed consent and injury compensation.

The central legal principle is that biotechnology innovation must operate within a system of scientific accountability, pharmaceutical quality control, patient protection and effective legal remedies.

18. Important Legal Sources and Research References

Legal sourceRelevance
Federal Law No. 61-FZ (2010)Pharmaceutical regulation
Federal Law No. 157-FZ (1998)Immunoprophylaxis and compensation
Federal Law No. 323-FZ (2011)Patient rights and healthcare
Federal Law No. 86-FZ (1996)Genetic engineering
Federal Law No. 152-FZ (2006)Personal data
Federal Law No. 2300-1 (1992)Consumer protection
Government Resolution No. 441 (2020)Special pandemic-era registration
Government Resolution No. 1013 (2000)Vaccine injury compensation
EAEU pharmaceutical rulesRegional registration and quality standards

Useful research materials:

Federal Law No. 61-FZ – On Circulation of Medicines.

Federal Law No. 157-FZ – On Immunoprophylaxis.

Federal Law No. 323-FZ – Public Health Protection.

Andreeva vaccine-administration judgment, 2022.

Krasnogorsk post-vaccination litigation, 2024.

University of Oxford – Russia COVID-19 Vaccine Compensation Scheme.

Comparative legal research on vaccine regulation in Russia.

Academic research note: The cited court decisions concern vaccine administration and post-vaccination injuries, not a direct judicial determination of the legality of Sputnik V's vector technology. For litigation or formal legal submissions, the current Russian-language statutory text, complete judgments and applicable amendments should be checked.

LawGratis provides pro bono legal aid and resources to empower communities. Join us in making justice reachable for everyone! Follow our community on Instagram, YouTube, Facebook, and LinkedIn.

LEAVE A COMMENT